Redeye comments on AlzeCure Pharma receiving orphan drug designation (ODD) from the European Medicines Agency (EMA) for its lead pain candidate ACD440 in erythromelalgia. We view the announcement as positive, as orphan drug status strengthens both the regulatory framework and commercial potential of the asset, while also enhancing its attractiveness in future partnering discussions.
LÄS MER
